Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, Mass.

Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...

(RTTNews) - Novartis AG (NVS), on Tuesday, announced that it has agreed to acquire privately held, clinical-stage biopharmaceutical company Anthos Therapeutics Inc. for up to $3.1 billion.

the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in ...

Novartis NOVN0.11%increase; green up pointing triangle said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to ...

Novartis agreed to acquire Blackstone Life Sciences' Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company retakes ...

Novartis has gone full circle with Anthos Therapeutics. The Swiss pharma giant is doubling down on its expertise in the cardiovascular area by acquiring the clinical-stage biotech firm mostly owned by ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline. The Swiss ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing ...